OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, today announced it has established a collaboration with the GOG Foundation, Inc., (GOG Foundation), to conduct a registration-enabled study of TAVO™ (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150).
January 7, 2019
· 6 min read